Technical Analysis for ATNWW - Actinium Pharmaceuticals Inc WT Ser B Exp 09/03/

Grade Last Price % Change Price Change
grade F 0.01 -91.67% -0.1100
ATNWW closed down 91.67 percent on Wednesday, January 22, 2020, on 44.88 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong N/A Down Down
Historical ATNWW trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
New 52 Week Closing Low Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Volume Surge Other 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Outside Day Range Expansion -91.67%
Wide Bands Range Expansion -91.67%
Older signals for ATNWW ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
Medicine Medical Specialties RTT Biopharmaceutical Clinical Medicine Cancers Acute Myeloid Leukemia Multiple Myeloma Leukemia Hematopoietic Stem Cell Transplantation Bone Marrow Transplant Cd135 Refractory Acute Myeloid Leukemia Actimab Camidanlumab Tesirine Refractory Multiple Myeloma Therapies For Patients With Cancers

Is ATNWW a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 0.55
52 Week Low 0.0001
Average Volume 234,249
200-Day Moving Average 0.0000
50-Day Moving Average 0.2046
20-Day Moving Average 0.1530
10-Day Moving Average 0.1300
Average True Range 0.0823
ADX 55.97
+DI 9.6461
-DI 52.2033
Chandelier Exit (Long, 3 ATRs ) 0.0031
Chandelier Exit (Short, 3 ATRs ) 0.2470
Upper Bollinger Band 0.2635
Lower Bollinger Band 0.0425
Percent B (%b) -0.15
BandWidth 144.4444
MACD Line -0.0333
MACD Signal Line -0.0275
MACD Histogram -0.0058
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0850
Resistance 3 (R3) 0.0933 0.0767 0.0725
Resistance 2 (R2) 0.0767 0.0576 0.0725 0.0683
Resistance 1 (R1) 0.0433 0.0458 0.0350 0.0350 0.0642
Pivot Point 0.0267 0.0267 0.0225 0.0225 0.0267
Support 1 (S1) -0.0067 0.0076 -0.0150 -0.0150 -0.0442
Support 2 (S2) -0.0233 -0.0042 -0.0275 -0.0483
Support 3 (S3) -0.0567 -0.0233 -0.0525
Support 4 (S4) -0.0650